Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Goldenwell Biotech (GWLL) Return on Equity (2020 - 2025)

Goldenwell Biotech's Return on Equity history spans 6 years, with the latest figure at 0.22% for Q3 2025.

  • For Q3 2025, Return on Equity rose 1060.0% year-over-year to 0.22%; the TTM value through Sep 2025 reached 0.22%, up 1060.0%, while the annual FY2024 figure was 7.02%, 620.0% down from the prior year.
  • Return on Equity reached 0.22% in Q3 2025 per GWLL's latest filing, down from 0.06% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 2.58% in Q4 2024 to a low of 10.83% in Q3 2024.
  • Average Return on Equity over 5 years is 2.22%, with a median of 0.39% recorded in 2022.
  • Peak YoY movement for Return on Equity: crashed -785bps in 2023, then skyrocketed 1060bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.37% in 2021, then plummeted by -1102bps to 4.49% in 2022, then skyrocketed by 73bps to 1.23% in 2023, then surged by 310bps to 2.58% in 2024, then plummeted by -109bps to 0.22% in 2025.
  • Per Business Quant, the three most recent readings for GWLL's Return on Equity are 0.22% (Q3 2025), 0.06% (Q2 2025), and 0.61% (Q1 2025).